WE GIVE SHAREHOLDERS A VOICE

Ardelyx Inc. Loss Submission Form

See If You Qualify For Monetary Reward

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Name *Please enter a name.

Email *Please enter a valid email.

Address

City

State

Zip

Daytime Phone

Evening Phone

Shares Owned

Purchase Date

Loss

Submit Transaction Detail Now (Optional)

Statement Information

- OR -

An attorney-client relationship is not created with the submission of this form, nor an obligation on the part of Levi & Korsinsky or you to file a lead plaintiff motion in this matter . The information you submit is held as confidential. If, in its sole discretion, Levi & Korsinsky believes that you might be an appropriate lead plaintiff candidate, Levi & Korsinsky will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases. Additionally, by submitting this form, you agree to receive an email providing you with login details for CORE (Compensation Recovery Monitoring System) to help you monitor and track your securities. This is a complimentary service. Thank you for submitting your details to Levi & Korsinsky.

FAX: 212-363-7171

Levi & Korsinsky, LLP announces that a ARDX class action lawsuit has been filed on behalf of investors who purchased Ardelyx Inc. (ARDX) securities between August 6, 2020 and July 19, 2021. For more on the ARDX Lawsuit please contact us today.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: the likelihood that tenapanor would be approved by the Food and Drug Administration (“FDA”). Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug’s treatment effect, making it foreseeably likely that the FDA would not approve the drug.

If you suffered a loss in you have until September 28, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Nicholas I. Porritt Partner

Nicholas I. Porritt, Partner

Mr. Porritt prosecutes securities class actions, shareholder class actions, derivative actions, and mergers and acquisitions litigations. As a qualified Solicitor of the Senior Courts of England & Wales, he advises international clients on the recovery of losses suffered in their investment portfolios.
Shannon L. Hopkins Partner

Shannon L. Hopkins, Partner

Ms. Hopkins manages the Firm’s Connecticut office. She has prosecuted a wide range of class action matters for over a decade, helping to recover millions in settlements on behalf of shareholders. Ms. Hopkins is also a Certified Public Accountant.
Joseph E. Levi Founding Partner

Joseph E. Levi, Founding Partner

Mr. Levi is a central figure in shaping and managing the Firm’s securities litigation practice. In addition to his efforts on behalf of shareholders, he has represented numerous patent holders in enforcing their patent rights.
Eduard Korsinsky Founding Partner

Eduard Korsinsky, Founding Partner

Mr. Korsinsky is a Managing Partner of the Firm. He has served as an Editor of the American Bar Association’s Securities Litigation Section newsletter. He represents clients in securities cases, derivative actions, consumer fraud and complex commercial matters.
Donald J. Enright Partner

Donald J. Enright, Partner

Mr. Enright’s practice focuses on shareholder mergers and acquisitions and securities fraud class action litigation. He has also handled matters in commodities, consumer fraud, and commercial litigation. He has served in a leadership role in numerous actions, yielding multi-million dollar recoveries for shareholder classes.

THE POWERHOUSE